Novartis Ag (NVS) Accumulated Expenses (2017 - 2025)

Novartis Ag (NVS) has 9 years of Accumulated Expenses data on file, last reported at $1.0 billion in Q4 2025.

• Quarterly Accumulated Expenses rose 518.34% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (up 518.34% YoY) and the FY2025 annual result came in at $1.0 billion, up 518.34% from the prior year.
• Accumulated Expenses improved to $1.0 billion in Q4 2025 per NVS's latest filing, from $169.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $1.1 billion in Q4 2022, with the low at $116.0 million in Q4 2023.
• Average Accumulated Expenses over 5 years is $503.2 million, with a median of $169.0 million recorded in 2024.
• Year-over-year, Accumulated Expenses soared 733.86% in 2022 and slumped 89.05% in 2023.
• Novartis Ag's Accumulated Expenses stood at $127.0 million in 2021, then jumped by 733.86% to $1.1 billion in 2022, then tumbled by 89.05% to $116.0 million in 2023, then soared by 45.69% to $169.0 million in 2024, then surged by 518.34% to $1.0 billion in 2025.
• Business Quant data shows NVS's Accumulated Expenses at $1.0 billion in Q4 2025, $169.0 million in Q4 2024, and $116.0 million in Q4 2023.